IP Library Granted Patent US 7,128,904
Granted Patent B2
US 7,128,904 · App. 10/052,239 · Granted Oct 31, 2006

Material containing metal ion ligand complex producing nitric oxide in contact with blood

Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,128,904
App. No.
10/052,239
Granted
Oct 31, 2006
Kind
B2
Abstract

Biocompatible materials that have the ability to release nitric oxide (NO) in situ at the surface-blood interface when in contact with blood. The materials which may be polymers (e.g., polyurethane, poly(vinyl chloride), silicone rubbers), metals, such as stainless steel, carbon, and the like are provided with biocatalysts or biomimetic catalysts on their surface that have nitrite, nitrate, and/or nitrosothiol-reducing capability. Illustratively, the catalysts are adsorbed or immobilized at the surface of the material. The catalysts can act on endogenous nitrite, nitrate, or nitrosothiols within the blood creating a local increase in the NO levels at the surface of the material. An illustrative enzymatic biocatalyst is mammalian xanthine oxidase. In another illustrative embodiment, a biomimetic catalyst is a copper (Cu(II)-ligand complex, e.g. dibenzo[e,k]-2,3,8,9-tetraphenyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene. In some cases, lipophilic salts of nitrite/nitrate (e.g., tridodecylmethylammonium nitrite (TDMA + NO 2 − /NO 3 − )) or certain salts of nitrosothiols can be doped within a polymer material, or an underlying polymeric film, to create a reservoir of nitrite or nitrosothiol that continuously leaks into the immobilized catalytic layer. Adequate levels of endogenous reducing equivalents are present within blood to provide catalytically-generated surface levels of NO that are above the threshold reportedly required to prevent platelet adhesion or activation.

Claims (15)

1. A material having a catalytic surface that has immobilized, or available at the surface thereof, a catalytic agent which is a metal ion ligand complex having nitrite reductase or nitrosothiol reductase activity, which converts nitrite/nitrate or nitrosothiols to nitric oxide when the catalytic surface is in contact with blood, wherein the material is a polymer, and the polymer includes lipophilic salts of nitrite/nitrate or nitrosothiols within the polymer to create a reservoir of nitrite/nitrate or nitrosothiol that can continuously leak to the catalytic surface.

2. The material of claim 1 wherein the lipophilic salt of nitrite/nitrate is tridodecylmethylammonium nitrite (TDMA + NO 2 − /NO 3 − ).

3. A material having a catalytic surface that has immobilized, or available at the surface thereof, a catalytic agent which is a metal ion ligand complex having nitrite reductase or nitrosothiol reductase activity, which converts nitrite/nitrate or nitrosothiols to nitric oxide when the catalytic surface is in contact with blood, wherein the material is a metal having the surface coated with a polymeric film having the catalytic agent incorporated into the film or attached to a surface of the polymeric film, and wherein the polymeric film her includes lipophilic salts of nitrite/nitrate or nitrosothiols within the polymer film to create a reservoir of nitrite/nitrate or nitrosothiol that can continuously leak to the catalytic surface.

4. A material having available at a surface thereof, a catalytic agent having nitrite reductase or nitrosothiol reductase activity, the catalytic agent including a ligand selected from dibenzo[e,k]-2,3,8,9-tetraphenyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene; dibenzo[e,k]-2,3,8,9-tetramethyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene; dibenzo[e,k]-2,3,8,9-tetraethyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene, and salts thereof.

5. The material of claim 4 , further comprising a polymer including lipophilic salts of nitrite/nitrate or nitrosothiols.

6. A material having a catalytic surface that has immobilized, or available at the surface thereof, a catalytic agent having nitrite reductase or nitrosothiol reductase activity, which converts nitrite/nitrate or nitrosothiols to nitric oxide when the catalytic surface is in contact with blood, wherein the catalytic agent is a Cu(II) metal ion ligand complex, and the ligand is selected from the group consisting of dibenzo[e,k]-2,3,8,9-tetraphenyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene; dibenzo[e,k]-2,3,8,9-tetramethyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene; and dibenzo[e,k]-2,3,8,9-tetraethyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene.

7. The material of claim 6 wherein the material is at least one of a polymer, a metal, an alloy of the metal, or graphite.

8. The material of claim 7 wherein the material is a polymer.

9. The material of claim 8 wherein the polymer is selected from the group of poly(vinyl chloride), polyurethane, and silicone rubber.

10. The material of claim 7 wherein the material is a metal.

11. The material of claim 10 wherein the metal is selected from the group consisting of stainless steel, nickel, titanium, aluminum, copper, gold, silver, platinum and alloys or combinations thereof.

12. The material of claim 10 wherein the catalytic agent is covalently attached to the surface of the metal material.

13. The material of claim 10 wherein the surface of the metal material is coated with a polymeric film having the catalytic agent incorporated into the film or attached to a surface of the polymeric film.

14. A medical device comprising:

a material having immobilized, or available at a surface thereof, a Cu(II) metal ion ligand complex having nitrite reductase or nitrosothiol reductase activity, which converts nitrite/nitrate or nitrosothiols to nitric oxide when in contact with blood, wherein the ligand of the Cu(II) metal ion ligand complex is selected from the group consisting of dibenzo[e,k]-2,3,8,9-tetraphenyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene; dibenzo[e,k]-2,3,8,9-tetraphenyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene; and dibenzo[e,k]-2,3,8,9-tetraethyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 11, 2018
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 047468/0307 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Sep 29, 2008
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021597/0543 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2002
From: BATCHELOR, MELISSA M.; OH, BONG KYUN; MEYERHOFF, MARK E.
To: REGENTS OF THE UNIVERSITY OF MICHIGAN, THE
Reel/Frame 012885/0406 →
Continuity (2)
Continuation In Part 6026201400 · Jan 16, 2001
Related Publication 20020115559A1 · Aug 22, 2002